106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2018 All rights reserved
ASCOPRO1873
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y/
Infectious Diseases Society of America Guideline. is resource is a practice tool based on ASCO
®
practice
guidelines and is not intended to substitute for the independent professional judgment of the treating
physician. Practice guidelines do not account for individual variation among patients. is pocket guide
does not purport to suggest any particular course of medical treatment. Use of the practice guidelines
and this resource are voluntary. e practice guidelines and additional information are available at
www.asco.org/supportive-care-guidelines. Copyright © 2018 by American Society of Clinical Oncolog y.
All rights reserved.
Abbreviations
ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte
count; AML, acute myeloid leukemia; ASCO, American Society of Clinical Oncolog y; CHOP,
cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin
™
), prednisone;
CR, complete response; ECOG, Eastern Cooperative Oncolog y Group; FN, febrile neutropenia;
HBV, hepatitis B virus; HSCT, Hematopoietic Stem Cell Transplantation; HSV, herpes simplex
virus; IDSA, Infectious Diseases Society of America; MDS, myelodysplastic syndromes; NCI,
National Cancer Institute; NHL, non-Hodgkin lymphoma; OMAS, oral mucositis assessment
scale; PR, partial response; VZV, varicella zoster virus
Source
Taplitz RA, Kennedy EB, Bow EJ, et al: Antimicrobial prophylaxis for adult patients with cancer-
related immunosuppression: ASCO and Infectious Diseases Society of America clinical practice
guideline update. J Clin Oncol. doi: 10.1200/JCO.18.00374
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical tools
and resources, is available at www.asco.org/supportive-care-guidelines
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
CB
Consensus-
based
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient
